Denise Scots-Knight
CIK: 0001297000
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (11 total)
- May 21, 2026ELAN
Elanco Animal Health Inc
Award(A)Direct4.7K shares- - May 21, 2026ELAN
Elanco Animal Health Inc
Award(A)Direct12.2K shares- - Feb 1, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
1M shares- - Feb 1, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
480K shares- - Feb 1, 2026MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
345K shares- - Nov 28, 2025ELAN
Elanco Animal Health Inc
Award(A)Direct10.3K shares- - Jan 25, 2025MREO
Mereo BioPharma Group plc
Award(A)DirectShare Options (Right to buy)
825K shares- - Nov 29, 2024ELAN
Elanco Animal Health Inc
Award(A)Direct18.2K shares- - Sep 13, 2024MREO
Mereo BioPharma Group plc
Sale(S)Direct60K shares at avg. $4.22$253K - Sep 12, 2024MREO
Mereo BioPharma Group plc
Sale(S)Direct28.6K shares at avg. $4.47$128K - Sep 11, 2024MREO
Mereo BioPharma Group plc
Exercise(M)Direct188.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 21, 2026 |  ELAN Elanco Animal Health Inc | Award(A) | 4,678 | - | $0 | Direct |
| May 21, 2026 | ELAN Elanco Animal Health Inc | Award(A) | 12,196 | - | $0 | Direct |
| Feb 1, 2026 |  MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 1,035,000 | - | - | Direct |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 480,000 | - | - | Direct |
| Feb 1, 2026 | MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 345,000 | - | - | Direct |
| Nov 28, 2025 | ELAN Elanco Animal Health Inc | Award(A) | 10,314 | - | - | Direct |
| Jan 25, 2025 | MREO Mereo BioPharma Group plc | Award(A) Share Options (Right to buy) | 825,000 | - | - | Direct |
| Nov 29, 2024 | ELAN Elanco Animal Health Inc | Award(A) | 18,169 | - | $0 | Direct |
| Sep 13, 2024 | MREO Mereo BioPharma Group plc | Sale(S) | 60,046 | $4.22 | $253,454 | Direct |
| Sep 12, 2024 | MREO Mereo BioPharma Group plc | Sale(S) | 28,611 | $4.47 | $127,968 | Direct |
| Sep 11, 2024 | MREO Mereo BioPharma Group plc | Exercise(M) | 188,060 | - | $0 | Direct |
1-11 of 11 transactions
About Scots-Knight Denise
Scots-Knight Denise (SEC CIK 0001297000) files insider reports with the SEC as Director of Elanco Animal Health Inc (ELAN) and Chief Executive Officer of Mereo BioPharma Group plc (MREO).
Signal8 holds 7 ownership filings by Scots-Knight Denise, all Form 4s, filed between Sep 13, 2024 and May 26, 2026. Those filings report 11 transactions, from Sep 11, 2024 to May 21, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Scots-Knight Denise's filings is in LONDON, X0.
Recent filings by Scots-Knight Denise
- May 21, 2026: Grants or awards of ELAN shares (2 lines, Form 4, code A).
- Feb 1, 2026: Grants or awards of MREO derivative securities (3 lines, Form 4, code A).
- Nov 28, 2025: Grant or award of ELAN shares (Form 4, code A).
- Jan 25, 2025: Grant or award of MREO derivative securities (Form 4, code A).
- Nov 29, 2024: Grant or award of ELAN shares (Form 4, code A).
Other insiders filing for Elanco Animal Health Inc (ELAN)
- Preston Jamie, EVP, Chief People Officer
- Modi Rajeev A.
- VanHimbergen Robert M, EVP and CFO
- Simmons Jeffrey N, PRESIDENT, CEO AND DIRECTOR
- Bettington Timothy J
- Anand Kapila K, Director